Aravive logo
Aravive ARAV

Quarterly report 2023-Q3
added 11-09-2023

report update icon

Aravive Financial Statements 2011-2026 | ARAV

Annual Financial Statements Aravive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

60.4 M 44.2 M 84.3 M 118 M 27.2 M 72.2 M 400 M 323 M 335 M 366 K 297 K 1.82 M

Shares

36.4 M 20.1 M 16.1 M 11.6 M 7.17 M 5.87 M 5.13 M 4.83 M 3.15 M 141 K 141 K 3.88 M

Historical Prices

1.66 2.2 6.81 8.54 5.83 9.6 131 39.4 119 - - -

Net Income

-76.3 M -39.2 M -30.5 M -18.2 M -76.3 M -85 M -95.8 M -82.2 M -57.5 M -18.5 M -13.2 M -7.17 M

Revenue

9.14 M 7.44 M 5.68 M 4.75 M 1.37 M 40 M - - - - - -

Gross Profit

- - 5.68 K - - - - - - - - -

Operating Income

-70.8 M -40.6 M -30.8 M -21.8 M -75.4 M -84.5 M -96.3 M -82.5 M -46.1 M -19.3 M -12.9 M -

Interest Expense

2.84 M 1.46 M -14 K 2.53 M 2.43 M 528 K 236 K 113 K -11.5 M 128 K 393 K -

EBITDA

-70 M -39.7 M -23.2 M -21.3 M -36 M -84.2 M -96.1 M -82.3 M -46 M -19.3 M -12.9 M -8.14 M

Operating Expenses

80 M 48.1 M 30.7 M 26.5 M 38.5 M 124 M 96.3 M 82.5 M 46.1 M 19.3 M 12.9 M 8.16 M

General and Administrative Expenses

13 M 10.6 M 13.1 M 13.7 M 27.4 M 29.9 M 24.3 M 22.5 M 13.5 M 4.43 M 1.94 M 1.78 M

All numbers in USD currency

Quarterly Income Statement Aravive

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

75.7 M 75.7 M 75.7 M 59.8 M 30.5 M 30.5 M 21.1 M 21 M 20.8 M 20.4 M 18.1 M 16.5 M 16.1 M 15.9 M 15 M 15 M 11.3 M 11.3 M 11.3 M 11.3 M 6.04 M 6.02 M 6 M 35.9 M 35.7 M 35.3 M 35 M 34.6 M 29.6 M 29.5 M 29.4 M 29.4 M 29.4 M 29.3 M 27.8 M 24.2 M 24.2 M 24.2 M 2.79 M 1.26 M 251 K 148 K 133 K - - - - - - - -

Net Income

21.2 M 18 M -50 M - -15.7 M -18.5 M -13.1 M - -11.1 M -7.1 M -8 M - -10.7 M -5.04 M -10.8 M - -6.14 M -3.04 M -4.7 M - -6.55 M -9.85 M -8.98 M 31.1 M -49.8 M -36.6 M -29.7 M -22.1 M -27.3 M -22.1 M -24.2 M -20.1 M -20.4 M -19.7 M -22 M -15.7 M -13.8 M -8.6 M -19.4 M -5.81 M -5.01 M -3.66 M -4.02 M - - - - - - - -

Revenue

2.76 M 1.27 M 1.49 M - 4.96 M 1.62 M 1.09 M - 2.41 M 3.79 M 256 K - - - - - 4.75 M 3.05 M 1.7 M - - - - 40 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.91 M -12.6 M -17.9 M - -16.5 M -19.4 M -15 M - -11.6 M -7.41 M -8.01 M - -10.7 M -5.72 M -10.3 M - -7 M -3.87 M -5.74 M - -6.22 M -9.44 M -8.52 M 31.1 M -49.7 M -36.2 M -29.7 M -22.5 M -27.4 M -22.3 M -24.1 M -20.2 M -20.5 M -19.5 M -22.3 M -15.9 M -14.1 M -8.5 M -7.58 M -5.86 M -5.26 M -3.98 M -4.18 M - - - - - - - -

Interest Expense

700 K 650 K 697 K - 738 K 705 K 703 K - 479 K 295 K -5 K - 31 K 656 K -701 K - 624 K 597 K 689 K - -593 K -656 K -657 K -547 K -262 K -521 K -261 K 446 K -39 K 59 K -230 K 32 K 91 K -236 K 226 K 244 K 208 K -141 K -11.8 M 44 K 128 K 128 K 128 K - - - - - - - -

EBITDA

- - -17.7 M - -15.9 M -19 M -14.8 M - -10.8 M -6.92 M -7.77 M - -9.1 M -4.57 M -10.2 M - -6.62 M -3.63 M -5.61 M - -5.24 M -9.2 M -8.4 M 31.1 M -49.6 M -36.1 M -29.6 M -22.5 M -27.3 M -22.2 M -24.1 M -20.2 M -20.4 M -19.4 M -22.2 M -15.9 M -14 M -8.48 M -7.58 M -5.86 M -5.25 M -3.97 M -4.18 M - - - - - - - -

Operating Expenses

11.7 M 13.9 M 19.4 M - 21.5 M 21 M 16.1 M - 14 M 11.2 M 8.26 M - 10.7 M 5.72 M 10.3 M - 7 M 6.93 M 7.44 M - 6.22 M 9.44 M 8.52 M 8.89 M 49.7 M 36.2 M 29.7 M 22.5 M 27.4 M 22.3 M 24.1 M 20.2 M 20.5 M 19.5 M 22.3 M 15.9 M 14.1 M 8.5 M 7.58 M 5.86 M 5.26 M 3.98 M 4.18 M - - - - - - - -

General and Administrative Expenses

2.94 M 3.07 M 3.49 M - 2.84 M 3.73 M 3.09 M - 2.64 M 3.08 M 2.38 M - 2.72 M 3.2 M 3.95 M - 3.16 M 3.29 M 4.59 M - 5.19 M 6 M 4.92 M 7.57 M 7.07 M 7.57 M 7.66 M 5.76 M 6.75 M 5.91 M 5.92 M 4.62 M 5.12 M 7.56 M 5.18 M 4.34 M 3.58 M 2.88 M 2.71 M 2.4 M 685 K 656 K 682 K - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aravive ARAV
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aravive plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
argenx SE argenx SE
ARGX
$ 700.45 -1.19 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.6 1.41 % $ 8.66 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.13 -5.06 % $ 105 M schweizSchweiz
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
$ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
$ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.6 -4.0 % $ 7.83 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA